The role of collateral related donors in haploidentical hematopoietic stem cell transplantation

被引:27
|
作者
Mo, Xiao-Dong [1 ]
Zhang, Yuan-Yuan [1 ]
Zhang, Xiao-Hui [1 ]
Xu, Lan-Ping [1 ]
Wang, Yu [1 ]
Yan, Chen-Hua [1 ]
Chen, Huan [1 ]
Chen, Yu-Hong [1 ]
Chang, Ying-Jun [1 ]
Liu, Kai-Yan [1 ]
Huang, Xiao-Jun [1 ,2 ,3 ]
机构
[1] Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
[2] Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
[3] Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
基金
中国国家自然科学基金;
关键词
Haploidentical; Hematopoietic stem cell transplantation; Collateral related donors; Paternal donors; Maternal donors; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; IDENTICAL-SIBLING TRANSPLANT; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHRONIC GRAFT; HEMATOLOGICAL MALIGNANCIES; UNRELATED DONORS; SINGLE-CENTER; RISK-FACTORS;
D O I
10.1016/j.scib.2018.08.008
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A key issue in the haploiedntical hematopoietic stem cell transplantation (haplo-HSCT) setting is the search for the best donor, because donor selection can significantly impact the clinical outcomes. We aimed to identify the role of collateral related donors (CRDs) in donor selection for haplo-HSCT through comparing the clinical outcomes between CRDs (n = 60) and maternal donors (MDs, n = 296), which were the last choice of donor selection in immediate related donors (IRDs). The cumulative incidence of graft-versus-host disease was comparable between CRDs and MDs. The 5-year cumulative incidence of relapse and non-relapse mortality was 22.0% (95% CI, 11.3%-32.7%) versus 17.4% (95% CI, 13.0%-21.8%) (P = 0.455) and 25.0% (95% CI, 13.9%-36.1%) versus 23.1% (95% CI, 18.2%-28.0%) (P = 0.721) for the CRDs and MDs, respectively. The 5-year probabilities of disease-free survival and overall survival was 53.2% (95% CI, 40.4%-66.0%) versus 59.5% (95% CI, 53.8%-65.2%) (P = 0.406) and 56.5% (95% CI, 43.8%-69.2%) versus 61.8% (95% CI, 56.1%-67.5%) (P = 0.458) for the CRDs and MDs, respectively. Female donor/male recipient (FDMR) CRDs were associated with the poorest clinical outcomes, and the clinical outcomes of non-FDMR CRDs were comparable to those of MDs. In summary, our results showed that CRDs did not showed superiority over MDs. Thus, IRDs should be the first choice of donor selection, and CRDs could only be the donors for those without IRDs. (C) 2018 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.
引用
收藏
页码:1376 / 1382
页数:7
相关论文
共 50 条
  • [31] Hematopoietic Stem Cell Transplantation for Leukemia
    Wayne, Alan S.
    Baird, Kristin
    Egeler, R. Maarten
    PEDIATRIC CLINICS OF NORTH AMERICA, 2010, 57 (01) : 1 - +
  • [32] Use of TK-cells in haploidentical hematopoietic stem cell transplantation
    Oliveira, Giacomo
    Greco, Raffaella
    Lupo-Stanghellini, Maria T.
    Vago, Luca
    Bonini, Chiara
    CURRENT OPINION IN HEMATOLOGY, 2012, 19 (06) : 427 - 433
  • [33] Tumor incidence in related hematopoietic stem cell donors
    Jeger, A.
    Favre, G.
    Lutz, J-M
    Stern, M.
    Usel, M.
    Rovo, A.
    Rischewski, J.
    Tichelli, A.
    Gratwohl, A.
    Halter, J.
    BONE MARROW TRANSPLANTATION, 2011, 46 (09) : 1240 - 1244
  • [34] Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy
    Kongtim, Piyanuch
    Lee, Dean A.
    Cooper, Laurence J. N.
    Kebriaei, Partow
    Champlin, Richard E.
    Ciurea, Stefan O.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (10) : 1714 - 1720
  • [35] Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma
    Liu, Anthony P. Y.
    Lee, Pamela P. W.
    Kwok, Janette S. Y.
    Leung, Rock Y. Y.
    Chiang, Alan K. S.
    Ha, Shau-Yin
    Cheuk, Daniel K. L.
    Chan, Godfrey C. F.
    PEDIATRIC TRANSPLANTATION, 2018, 22 (06)
  • [36] Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
    Slade, Michael
    Goldsmith, Scott
    Romee, Rizwan
    DiPersio, John F.
    Dubberke, Erik R.
    Westervelt, Peter
    Uy, Geoffrey L.
    Lawrence, Steven J.
    TRANSPLANT INFECTIOUS DISEASE, 2017, 19 (01)
  • [37] Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy
    Mo, Xiao-Dong
    Zhang, Xiao-Hui
    Xu, Lan-Ping
    Wang, Yu
    Yan, Chen-Hua
    Chen, Huan
    Chen, Yu-Hong
    Han, Wei
    Wang, Feng-Rong
    Wang, Jing-Zhi
    Liu, Kai-Yan
    Huang, Xiao-Jun
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (12) : 2235 - 2242
  • [38] Hematopoietic stem cell transplantation. Indications, foundations and perspective
    Buchholz, S.
    Ganser, A.
    INTERNIST, 2009, 50 (05): : 572 - +
  • [39] Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation
    Rovatti, Pier Edoardo
    Gambacorta, Valentina
    Lorentino, Francesca
    Ciceri, Fabio
    Vago, Luca
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [40] Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia
    Harada, Kaito
    Mizuno, Shohei
    Yano, Shingo
    Takami, Akiyoshi
    Ishii, Hiroto
    Ikegame, Kazuhiro
    Najima, Yuho
    Kako, Shinichi
    Ashida, Takashi
    Shiratori, Souichi
    Ota, Shuichi
    Onizuka, Makoto
    Fukushima, Kentaro
    Fukuda, Takahiro
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Yanada, Masamitsu
    ANNALS OF HEMATOLOGY, 2022, 101 (03) : 643 - 653